IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v36y2018i8d10.1007_s40273-018-0654-1.html
   My bibliography  Save this article

Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China

Author

Listed:
  • Yuqing Tang

    (Huazhong University of Science and Technology)

  • Chaojie Liu

    (La Trobe University)

  • Junjie Liu

    (Huazhong University of Science and Technology)

  • Xinping Zhang

    (Huazhong University of Science and Technology)

  • Keyuan Zuo

    (Hubei Public Resource Trading Center)

Abstract

Background The overuse of antibiotics has become a major public health challenge worldwide, especially in low- and middle-income countries, including China. In 2009, the Chinese government launched a series of measures to de-incentivise over-prescription in public health facilities, including decoupling the link between facility income and the sale of medicines. Objectives We evaluated the effects of these measures on procurement costs and the volume of antibiotics in county public hospitals. Methods The study was undertaken in the Hubei province of China, where 64 county public hospitals implemented the reform in sequence at three different stages. A quasi-natural experiment design was employed. We performed generalised linear regressions with a difference-in-differences approach using 22,713 procurement records of antibiotics from November 2014 to December 2016. Results The regression results showed that the reform contributed to a 14.79% increase in total costs for antibiotics (p = 0.013), particularly costs for injectable antibiotics (p = 0.022) and first-line antibiotics (p = 0.030). The procurement prices for antibiotics remained largely comparable to those in the control group, but the reform led to a 17.30% increase in the procurement volume (expressed as defined daily doses) of second-line antibiotics (p = 0.032). Conclusions County public hospitals procured more antibiotics and greater numbers of expensive antibiotics, such as those administered via injection, to compensate for the loss of income from the sale of medicines, leading to an increased total cost of antibiotics.

Suggested Citation

  • Yuqing Tang & Chaojie Liu & Junjie Liu & Xinping Zhang & Keyuan Zuo, 2018. "Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China," PharmacoEconomics, Springer, vol. 36(8), pages 995-1004, August.
  • Handle: RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0654-1
    DOI: 10.1007/s40273-018-0654-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-018-0654-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-018-0654-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Yang, Wei, 2016. "How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai," Health Economics, Policy and Law, Cambridge University Press, vol. 11(4), pages 379-395, October.
    2. Yuting Zhang & Qianheng Ma & Yingchun Chen & Hongxia Gao, 2017. "Effects of Public Hospital Reform on Inpatient Expenditures in Rural China," Health Economics, John Wiley & Sons, Ltd., vol. 26(4), pages 421-430, April.
    3. Reynolds, Lucy & McKee, Martin, 2009. "Factors influencing antibiotic prescribing in China: An exploratory analysis," Health Policy, Elsevier, vol. 90(1), pages 32-36, April.
    4. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    5. Hu, Jia & Mossialos, Elias, 2016. "Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts," Health Policy, Elsevier, vol. 120(5), pages 519-534.
    6. Robert Evans & Alan Maynard & Alexander Preker & Uwe Reinhardt, 1994. "Health care reform," Health Economics, John Wiley & Sons, Ltd., vol. 3(6), pages 359-359, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Fu, Hongqiao & Li, Ling & Yip, Winnie, 2018. "Intended and unintended impacts of price changes for drugs and medical services: Evidence from China," Social Science & Medicine, Elsevier, vol. 211(C), pages 114-122.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kanavos, Panos & Mills, Mackenzie & Zhang, Anwen, 2019. "Pharmaceutical policy in China," LSE Research Online Documents on Economics 108473, London School of Economics and Political Science, LSE Library.
    2. Cheo, Roland & Ge, Ge & Godager, Geir & Liu, Rugang & Wang, Qiqi & Wang, Jian, 2018. "The effect of a mystery shopper scheme on prescriptions in primary care," HERO Online Working Paper Series 2018:1, University of Oslo, Health Economics Research Programme.
    3. Shu Yan & Lizi Pan & Yan Lu & Juan Chen & Ting Zhang & Dongzi Xu & Zhaolian Ouyang, 2023. "Towards Sustainable Drug Supply in China: A Bibliometric Analysis of Drug Reform Policies," Sustainability, MDPI, vol. 15(13), pages 1-20, June.
    4. Shi, Wunan & Wouters, Olivier J. & Liu, Gordon & Mossialos, Elias & Yang, Xiuyun, 2020. "Association between provincial income levels and drug prices in China over the period 2010–2017," Social Science & Medicine, Elsevier, vol. 263(C).
    5. Qian Long & Weixi Jiang & Di Dong & Jiaying Chen & Li Xiang & Qiang Li & Fei Huang & Henry Lucas & Shenglan Tang, 2020. "A New Financing Model for Tuberculosis (TB) Care in China: Challenges of Policy Development and Lessons Learned from the Implementation," IJERPH, MDPI, vol. 17(4), pages 1-11, February.
    6. Zhongliang Zhou & Yu Fang & Zhiying Zhou & Dan Li & Dan Wang & Yanli Li & Li Lu & Jianmin Gao & Gang Chen, 2017. "Assessing Income-Related Health Inequality and Horizontal Inequity in China," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 132(1), pages 241-256, May.
    7. Mike McKenna & Alan Maynard & Ken Wright, 1992. "Is rehabilitation cost effective?," Working Papers 101chedp, Centre for Health Economics, University of York.
    8. Han, Euna & Chae, Su-Mi & Kim, Nam-Soon & Park, Sylvia, 2015. "Effects of pharmaceutical cost containment policies on doctors’ prescribing behavior: Focus on antibiotics," Health Policy, Elsevier, vol. 119(9), pages 1245-1254.
    9. Xuan Wang & Yuqing Tang & Xiaopeng Zhang & Xi Yin & Xin Du & Xinping Zhang, 2014. "Effect of Publicly Reporting Performance Data of Medicine Use on Injection Use: A Quasi-Experimental Study," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-7, October.
    10. Barros, Pedro Pita & Nunes, Luis C., 2010. "The impact of pharmaceutical policy measures: An endogenous structural-break approach," Social Science & Medicine, Elsevier, vol. 71(3), pages 440-450, August.
    11. Yu Xia & Jing Li & Zhongyang Zhang, 2023. "Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy," Operational Research, Springer, vol. 23(4), pages 1-27, December.
    12. Jiannan Li & Bocong Yuan, 2019. "Rural‐urban disparity in risk exposure to involuntary social health insurance transition in China: An investigation of chronic disease patients' mental health problems," International Journal of Health Planning and Management, Wiley Blackwell, vol. 34(4), pages 1760-1773, October.
    13. Stéphane Jacobzone, 1996. "Les politiques de santé face aux propriétés incitatives et redistributives des systèmes d'assurance-maladie," Économie et Statistique, Programme National Persée, vol. 291(1), pages 49-70.
    14. Kwon, Hye-Young & Hong, Ji-Min & Godman, Brian & Yang, Bong-Min, 2013. "Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents," Health Policy, Elsevier, vol. 112(3), pages 217-226.
    15. JunQiang Liu & Tao Chen, 2013. "Sleeping money: investigating the huge surpluses of social health insurance in China," International Journal of Health Economics and Management, Springer, vol. 13(3), pages 319-331, December.
    16. Zhiyang Shen & Vivian Valdmanis, 2020. "Identifying the contribution to hospital performance among Chinese regions by an aggregate directional distance function," Health Care Management Science, Springer, vol. 23(1), pages 142-152, March.
    17. Han, Euna & Park, Sun-Young & Lee, Eui-Kyung, 2016. "Assessment of the Price–Volume Agreement Program in South Korea," Health Policy, Elsevier, vol. 120(10), pages 1209-1215.
    18. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    19. Maria-Manuel Azevedo & Céline Pinheiro & John Yaphe & Fátima Baltazar, 2013. "Assessing the Impact of a School Intervention to Promote Students’ Knowledge and Practices on Correct Antibiotic Use," IJERPH, MDPI, vol. 10(7), pages 1-12, July.
    20. Zhibek Omarkhanova & Danagul Tleuzhanova & Aigul Zholmukhanova & Zamira Mukhambetova & Sholpan Alpeissova, 2020. "Comparative analysis of social and economic efficiency in managing product innovations in the pharmaceutic industry," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 8(2), pages 1245-1266, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:36:y:2018:i:8:d:10.1007_s40273-018-0654-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.